Cutting-edge clinical cancer research solutions from Illumina deliver the accurate information your lab needs to improve the quality of your reporting and optimize care. Rapidly analyze expert-defined genes and mutation hotspots to find actionable variants in any type of cancer, including solid tumors and hematological malignancies.
Our workflow solutions for translational cancer research include both fixed and customizable cancer panels and a comprehensive range of systems that can be scaled to meet your needs. Our multi-analyte approach enables you to get thorough information efficiently and cost-effectively, even from small specimens. In addition, these integrated solutions include data analysis and reporting capabilities to help you communicate significant findings effectively.
See how the latest advances in genomic technologies can help to identify important mutations in cancer.
Jaclyn Hechtman, MD, Associate Attending Pathologist at Memorial Sloan Kettering Cancer Center, discusses the relevance of RET alterations in non-small cell lung cancer and the pros and cons of different technical approaches to identify RET fusions and single-nucleotide variants.View Webinar
An NGS panel enables translational cancer researchers to seek answers to multiple questions in one assay.Read Interview
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.Read Interview
The latest additions to the Illumina portfolio of comprehensive cancer profiling assays provide labs with the flexibility to run tissue or blood plasma samples on a single high-throughput platform.Read Article
The MiniSeq System delivers cost-efficient, reliable sequencing for low-throughput clinical cancer research labs. Perform accurate profiling of solid tumors, hematological cancers, and germline mutations on your benchtop.View System